Investigation Report on China's Sodium Hyaluronate Market 2015

News provided by

Sep 04, 2015, 07:10 ET

DUBLIN, Sep. 04, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/dvzsqg/investigation) has announced the addition of the "Investigation Report on China's Sodium Hyaluronate Market, 2010-2019" report to their offering.

Sodium hyaluronate is a long-chain polymer containing repeating disaccharide units of Na-glucuronate-N-acetylglucosamine. As a major ingredient of synovial fluid and cartilage matrix, sodium hyaluronate can lubricate the joint, protect cartilage of the joint, improve joint contracture and pathological articular fluid. Sodium hyaluronate eye drop is used for the treatment of dry eyes and mechanical lesion to corneal endothelium while sodium hyaluronate injection is used as a joint function-improving agent for intra-articular injection on osteoarthropathy patients.

Currently, only sodium hyaluronate injection and eye drop are available in the market. The raw materials of sodium hyaluronate can be classified into pharmaceutical grade, external grade and edible grade.

Currently, hyaluronate is mainly used as the raw material of artificial synovial fluid and eye drops after eye surgery which together brought in a global sales value of USD 700-800 million. This figure is estimated to reach up to USD 3 billion if its cosmetics are counted too.

In the middle of 1990s, preparations of sodium hyaluronate began to be used in the clinic in China, achieving good efficacy in ophthalmology, orthopaedics and surgery. Sodium hyaluronate develops fast after entering China, annual sales value rising from less than CNY 100 million in 2005 to CNY 290 million in 2014 and CAGR during this period reaching 18.61%. Sodium hyaluronate enjoys a vast demand in China. Seikagaku Corporation (Japan), United Laboratories, Bausch & Lomb, Santen Pharmaceutical Co., Ltd (Japan), Shanghai Jingfeng Pharmaceutical Co., Ltd and URSAPHARM Arzneimittel GmbH Co.KG (GE) all take up certain shares in the market, among of which Seikagaku Corporation (Japan) has the largest market share of 29% for sales value in 2014.

Over the last decade, the demand for sodium hyaluronate in the area of health has kept increasing. With the ever-growing demand of life quality and the rapid aging of the urban population, senile diseases like cataract and osteoarthritis, the market size of sodium hyaluronate will continue to expand in China.

Companies Mentioned

- United Laboratories
- Bausch & Lomb
- Shanghai Jingfeng Pharmaceutical Co., Ltd
- Shanghai Haohai Biological Technology Co., Ltd
- Santen Pharmaceutical Co., Ltd (Japan)

For more information visit http://www.researchandmarkets.com/research/dvzsqg/investigation